



ISPOR 18th Annual European Congress

7-11 November 2015
MiCo - Milano Congressi
Milan, Italy

JOINT ASSESSMENTS IN EUROPE: CAN WE DO IT AND HOW?

The HTA Core Model and its use in Joint Assessment

Luciana Ballini – Agenzia Sanitaria e Sociale Regionale-
Emilia-Romagna (ASSR-RER) - Italy



eunetha

The HTA European Collaboration goals

Efficiency

- Timely information
- Less duplication
- Re-use and local adaptation
- Greater coverage of topics

Quality

- Shared methodology
- New/emerging methodological challenges

Availability of evidence

- Communication of evidence needs
- Dealing with research gaps

Sharing trustworthy assessments

- Joint products, collaborative products, re-use of local products




eunetha

Joint Assessment – National Uptake

Rapid REA Drugs	Up take	Rapid REA MD	Up take	Full HTA	Up take
<i>New pharmaceuticals for the treatment of chronic hepatitis C (inpress)</i>		<i>Endovascular therapy using mechanical thrombectomy devices for acute ischaemic stroke (in press)</i>		<i>Structured telephone support (STS) for adult patients with chronic heart failure (in press)</i>	
Vorapaxar for the reduction of cardiovascular events		Transcatheter implantable devices for mitral valve repair		<i>Intravenous immunoglobulins for Mild Cognitive Impairment and Alzheimer's disease (In press)</i>	
Ramucirumab + Paclitaxel for the treatment of gastric cancer	PPP PPP	Biodegradable stents for the treatment of oesophageal stenosis	PPP P	ColoRectal Cancers screening tests	PPP P
sorafenib as a treatment of thyroid carcinoma	PPP PP	Balloon Eustachian Tuboplasty for Eustachian tube dysfunction	PPP P	Abdominal Aorta Aneurysm Screening (AAA)	PPP
canagliflozin as a treatment of type 2 diabetes mellitus	PPP PPP PP	Renal denervation systems for treatment-resistant hypertension	PPP PPP PPP	Prognostic tests for breast cancer recurrence (PTBCR)	
Zostavax for the prevention herpes zoster'	PPP P	Duodenal-jejunal bypass sleeve for the treatment of obesity	PPP PPP		

The HTA Core Model®



Description

The HTA Core Model® is a methodological **framework for shared production and sharing of HTA information**

Purpose

To enable **production of high quality HTA information in a structured format** to support the **production of local (national or regional) HTAs and reuse of existing information**

A practical tool to implement transnational collaborative HTA work that:

- stems from a long and complex process of revision**

Version 2.0


Version 2.1

Version 3.0

Version 4.0

The Domains of the HTA Core Model®


- answering **questions to aid decisions**



HTA and context


Globalize the evidence,
localize the decision

J.M. Eisenberg



Locate the decision, globalise the
evidence, localise the reporting


EUnetHTA



The Domains of the HTA Core Model®

- **global evidence for local decisions**

HTA Core Model DOMAINS
1. Health problem and current use of technology
2. Description and technical characteristics
3. Safety
4. Clinical effectiveness
5. Costs and economic evaluation
6. Ethical analysis
7. Organisational aspects
8. Patient and social aspects
9. Legal aspects



The Domains of the HTA Core Model®

- global evidence for local decisions

HTA Core Model DOMAINS

1. Health problem and current use of technology
2. Description and technical characteristics
3. Safety
4. Clinical effectiveness
5. Costs and economic evaluation
6. Ethical analysis
7. Organisational aspects
8. Patient and social aspects
9. Legal aspects

GLOBAL

Systematic Review of Literature
Methods of analysis
Endpoint and issues




LOCAL

Use of Systematic reviews for
Methods in primary research and
analysis
Budget impact/equity issues/
organizational needs ...

The Domains of the HTA Core Model®


- **global evidence for local decisions**



Global evidence to support local decisions

- Ø Transparency and accountability of decisions
- Ø Variations explained and understood
- Ø Higher predictability of market and health expenditures
- Ø Decrease discrepancies in care across borders

Health Technology Life-cycle



Thank you

This presentation arises from the EUnetHTA Joint Action 2 which has received funding from the European Union, in the framework of the Health Programme